Tirzepatide adds GIP receptor activation for enhanced weight loss, and next-generation triple agonists are adding glucagon receptor activation to increase caloric burn
Zhao Z, Wang J, Kong W, Newton MA, Burkett WC, Sun W, et al
Here's what the data shows: 10.6% average weight loss in just 24 weeks Twice the efficacy of currently approved obesity drugs Oral tablets - no weekly injections required Triple mechanism targeting dopamine, serotonin AND norepinephrine The most impressive part
As detailed in AARPs coverage guide updated on November 21, 2025, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D plans from covering medications prescribed primarily for weight loss as part of the standard benefit
25 Liraglutide Isnt WorkingShould I Switch to Semaglutide